PMID- 30758476
OWN - NLM
STAT- MEDLINE
DCOM- 20190624
LR  - 20200225
IS  - 2317-6326 (Electronic)
IS  - 0102-6720 (Print)
IS  - 0102-6720 (Linking)
VI  - 32
IP  - 1
DP  - 2019 Feb 7
TI  - PANCREATIC NEUROENDOCRINE TUMORS: SURGICAL RESECTION.
PG  - e1428
LID - S0102-67202019000100502 [pii]
LID - 10.1590/0102-672020180001e1428 [doi]
LID - e1428
AB  - INTRODUCTION: Pancreatic neuroendocrine tumors (pNET) correspond to about 3% of 
      all tumors in pancreas and could be presented as a difficult diagnosis and 
      management. OBJECTIVE: To review the diagnosis and treatment of the pNET 
      available in scientific literature. METHOD: A bibliographic survey was performed 
      by means of an online survey of MeSH terms in the Pubmed database. A total of 104 
      articles were published in the last 15 years, of which 23 were selected as the 
      basis for the writing of this article. RESULTS: pNET is an infrequent neoplasia 
      and their incidence, in USA, is about 1:100.000 inhabitants/year. Thereabout 30% 
      of them produce hormones presenting as a symptomatic disease and others 70% of 
      the cases could be silent disease. Magnetic Resonance Imaging (MRI) and/or 
      Computed Tomography (CT) have similar sensitivy to detect pNET. They are very 
      important when associated to nuclear medicine mainly Positron Emission Tomography 
      (PET-CT) Gallium-68 to find primary tumor and its staging. The appropriate 
      treatment should be chosen based on characteristics of the tumor, its staging and 
      associated comorbidities. CONCLUSION: The surgical resection is still the best 
      treatment for patients with ressectable pancreatic NETs. However, the size, 
      grade, tumor functionality, stage and association with multiple endocrine 
      neoplasia type 1 (MEN-1) are important to define who will be eligible for 
      surgical treatment. In general, tumors bigger than 2 cm are eligible for surgical 
      treatment, except insulinomas whose surgical resection is recommended no matter 
      the size.
FAU - Belotto, Marcos
AU  - Belotto M
AD  - Depa, German Hospital Oswaldo Cruz.
FAU - Crouzillard, Bruna do Nascimento Santos
AU  - Crouzillard BDNS
AD  - Faculty of Medical Sciences, Santa Casa de Sao Paulo.
FAU - Araujo, Karla de Oliveira
AU  - Araujo KO
AD  - Depa, German Hospital Oswaldo Cruz.
FAU - Peixoto, Renata D'Alpino
AU  - Peixoto RD
AD  - Oncology Service, Nove de Julho University, Sao Paulo, SP, Brazil.
LA  - eng
LA  - por
PT  - Journal Article
PT  - Review
DEP - 20190207
PL  - Brazil
TA  - Arq Bras Cir Dig
JT  - Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of 
      digestive surgery
JID - 9100283
RN  - Gastro-enteropancreatic neuroendocrine tumor
SB  - IM
MH  - Humans
MH  - Intestinal Neoplasms/*surgery
MH  - Magnetic Resonance Imaging
MH  - Neoplasm Staging
MH  - Neuroendocrine Tumors/*surgery
MH  - Pancreatic Neoplasms/*surgery
MH  - Stomach Neoplasms/*surgery
MH  - Tomography, X-Ray Computed
PMC - PMC6368164
COIS- Conflict of interest: none
EDAT- 2019/02/14 06:00
MHDA- 2019/06/25 06:00
PMCR- 2019/02/07
CRDT- 2019/02/14 06:00
PHST- 2018/06/14 00:00 [received]
PHST- 2018/10/16 00:00 [accepted]
PHST- 2019/02/14 06:00 [entrez]
PHST- 2019/02/14 06:00 [pubmed]
PHST- 2019/06/25 06:00 [medline]
PHST- 2019/02/07 00:00 [pmc-release]
AID - S0102-67202019000100502 [pii]
AID - 10.1590/0102-672020180001e1428 [doi]
PST - epublish
SO  - Arq Bras Cir Dig. 2019 Feb 7;32(1):e1428. doi: 10.1590/0102-672020180001e1428.